WO2002099133A1 - Procede ameliore de detection et d'identification de micro-organismes causes d'infections - Google Patents
Procede ameliore de detection et d'identification de micro-organismes causes d'infections Download PDFInfo
- Publication number
- WO2002099133A1 WO2002099133A1 PCT/JP2002/005107 JP0205107W WO02099133A1 WO 2002099133 A1 WO2002099133 A1 WO 2002099133A1 JP 0205107 W JP0205107 W JP 0205107W WO 02099133 A1 WO02099133 A1 WO 02099133A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- units
- minutes
- cells
- solution
- Prior art date
Links
- 244000005700 microbiome Species 0.000 title claims abstract description 42
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims description 93
- 210000001539 phagocyte Anatomy 0.000 claims abstract description 68
- 238000001514 detection method Methods 0.000 claims abstract description 42
- 239000012528 membrane Substances 0.000 claims abstract description 34
- 239000003298 DNA probe Substances 0.000 claims abstract description 30
- 108020003215 DNA Probes Proteins 0.000 claims abstract description 24
- 230000035699 permeability Effects 0.000 claims abstract description 9
- 239000000523 sample Substances 0.000 claims description 210
- 210000004027 cell Anatomy 0.000 claims description 136
- 102000004190 Enzymes Human genes 0.000 claims description 97
- 108090000790 Enzymes Proteins 0.000 claims description 97
- 229940088598 enzyme Drugs 0.000 claims description 97
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 66
- 239000011521 glass Substances 0.000 claims description 60
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical group FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 claims description 60
- 238000011282 treatment Methods 0.000 claims description 48
- 238000009396 hybridization Methods 0.000 claims description 41
- 108010014251 Muramidase Proteins 0.000 claims description 40
- 102000016943 Muramidase Human genes 0.000 claims description 40
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 claims description 40
- 239000004325 lysozyme Substances 0.000 claims description 40
- 235000010335 lysozyme Nutrition 0.000 claims description 40
- 229960000274 lysozyme Drugs 0.000 claims description 40
- 208000035473 Communicable disease Diseases 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 238000007901 in situ hybridization Methods 0.000 claims description 28
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 27
- 239000004094 surface-active agent Substances 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 21
- 239000008280 blood Substances 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 20
- 239000000126 substance Substances 0.000 claims description 18
- 108010033128 Glucan Endo-1,3-beta-D-Glucosidase Proteins 0.000 claims description 17
- 108090000988 Lysostaphin Proteins 0.000 claims description 17
- 206010040047 Sepsis Diseases 0.000 claims description 12
- 239000003945 anionic surfactant Substances 0.000 claims description 9
- 208000031729 Bacteremia Diseases 0.000 claims description 8
- 238000012544 monitoring process Methods 0.000 claims description 5
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 238000011065 in-situ storage Methods 0.000 claims description 3
- 230000035484 reaction time Effects 0.000 claims description 3
- 150000001768 cations Chemical class 0.000 claims description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 230000003466 anti-cipated effect Effects 0.000 abstract 1
- 230000003100 immobilizing effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 127
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 68
- 230000000242 pagocytic effect Effects 0.000 description 62
- 210000000265 leukocyte Anatomy 0.000 description 61
- 108020004414 DNA Proteins 0.000 description 59
- -1 for example Substances 0.000 description 56
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 50
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 45
- 239000003153 chemical reaction reagent Substances 0.000 description 41
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 40
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 241000894006 Bacteria Species 0.000 description 35
- 230000000694 effects Effects 0.000 description 30
- 210000004379 membrane Anatomy 0.000 description 29
- 206010057249 Phagocytosis Diseases 0.000 description 27
- 230000008782 phagocytosis Effects 0.000 description 27
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 24
- 239000011780 sodium chloride Substances 0.000 description 23
- 108010060371 endo-N-acetylmuramidase Proteins 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 20
- 241000191967 Staphylococcus aureus Species 0.000 description 20
- 239000011550 stock solution Substances 0.000 description 20
- 241000191963 Staphylococcus epidermidis Species 0.000 description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 17
- 230000001580 bacterial effect Effects 0.000 description 17
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 17
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 17
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 235000014113 dietary fatty acids Nutrition 0.000 description 15
- 239000000194 fatty acid Substances 0.000 description 15
- 229930195729 fatty acid Natural products 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 241000194033 Enterococcus Species 0.000 description 13
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 12
- 238000004040 coloring Methods 0.000 description 12
- 239000008213 purified water Substances 0.000 description 12
- 230000009089 cytolysis Effects 0.000 description 11
- 239000006228 supernatant Substances 0.000 description 11
- 229910019142 PO4 Inorganic materials 0.000 description 10
- 235000021317 phosphate Nutrition 0.000 description 10
- 241000222122 Candida albicans Species 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 9
- 229940095731 candida albicans Drugs 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 150000004665 fatty acids Chemical class 0.000 description 9
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 8
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 8
- 241000194032 Enterococcus faecalis Species 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 8
- 239000004365 Protease Substances 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 7
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 7
- 230000021736 acetylation Effects 0.000 description 7
- 238000006640 acetylation reaction Methods 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 229940032049 enterococcus faecalis Drugs 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 102000004594 DNA Polymerase I Human genes 0.000 description 6
- 108010017826 DNA Polymerase I Proteins 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- 239000002280 amphoteric surfactant Substances 0.000 description 6
- 238000009640 blood culture Methods 0.000 description 6
- 239000003093 cationic surfactant Substances 0.000 description 6
- 239000003599 detergent Substances 0.000 description 6
- 229960001484 edetic acid Drugs 0.000 description 6
- 230000002101 lytic effect Effects 0.000 description 6
- 229960002337 magnesium chloride Drugs 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 239000002736 nonionic surfactant Substances 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000011543 agarose gel Substances 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 5
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 5
- 239000010452 phosphate Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 229940037645 staphylococcus epidermidis Drugs 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 3
- RZSYLLSAWYUBPE-UHFFFAOYSA-L Fast green FCF Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC(O)=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 RZSYLLSAWYUBPE-UHFFFAOYSA-L 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 235000005811 Viola adunca Nutrition 0.000 description 3
- 240000009038 Viola odorata Species 0.000 description 3
- 235000013487 Viola odorata Nutrition 0.000 description 3
- 235000002254 Viola papilionacea Nutrition 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000007605 air drying Methods 0.000 description 3
- 150000005215 alkyl ethers Chemical class 0.000 description 3
- 125000005037 alkyl phenyl group Chemical group 0.000 description 3
- 125000000129 anionic group Chemical group 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 229940068977 polysorbate 20 Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical class C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 2
- BMYCCWYAFNPAQC-UHFFFAOYSA-N 2-[dodecyl(methyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCN(C)CC(O)=O BMYCCWYAFNPAQC-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 241000222178 Candida tropicalis Species 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 241000588697 Enterobacter cloacae Species 0.000 description 2
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 2
- 239000004214 Fast Green FCF Substances 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000191938 Micrococcus luteus Species 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 241000235648 Pichia Species 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 2
- RDFCSSHDJSZMTQ-ZDUSSCGKSA-N Tos-Lys-CH2Cl Chemical compound CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 RDFCSSHDJSZMTQ-ZDUSSCGKSA-N 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 241000192402 [Candida] galacta Species 0.000 description 2
- 230000000397 acetylating effect Effects 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 150000008051 alkyl sulfates Chemical class 0.000 description 2
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000012916 chromogenic reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000012869 ethanol precipitation Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 235000019240 fast green FCF Nutrition 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 229920002114 octoxynol-9 Polymers 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- KSYNLCYTMRMCGG-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O KSYNLCYTMRMCGG-UHFFFAOYSA-J 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- NLEBIOOXCVAHBD-YHBSTRCHSA-N (2r,3r,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-dodecoxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](OCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 NLEBIOOXCVAHBD-YHBSTRCHSA-N 0.000 description 1
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 1
- KCVIRDLVBXYYKD-UHFFFAOYSA-O 1-nitrotetrazol-2-ium Chemical compound [O-][N+](=O)[NH+]1C=NN=N1 KCVIRDLVBXYYKD-UHFFFAOYSA-O 0.000 description 1
- BHNQPLPANNDEGL-UHFFFAOYSA-N 2-(4-octylphenoxy)ethanol Chemical compound CCCCCCCCC1=CC=C(OCCO)C=C1 BHNQPLPANNDEGL-UHFFFAOYSA-N 0.000 description 1
- GWEBEJYKXBMRJL-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;1-dodecoxydodecane;sulfuric acid Chemical compound OS(O)(=O)=O.OCCN(CCO)CCO.CCCCCCCCCCCCOCCCCCCCCCCCC GWEBEJYKXBMRJL-UHFFFAOYSA-N 0.000 description 1
- MACVUTCNLULHLQ-UHFFFAOYSA-N 2-[methyl(octadecanoyl)amino]ethanesulfonic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(=O)N(C)CCS(O)(=O)=O MACVUTCNLULHLQ-UHFFFAOYSA-N 0.000 description 1
- MUHFRORXWCGZGE-KTKRTIGZSA-N 2-hydroxyethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCO MUHFRORXWCGZGE-KTKRTIGZSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 240000008025 Alternanthera ficoidea Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010001986 Amoebic dysentery Diseases 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 241000606124 Bacteroides fragilis Species 0.000 description 1
- 102100032487 Beta-mannosidase Human genes 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- ONAIRGOTKJCYEY-XXDXYRHBSA-N CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 Chemical group CCCCCCCCCCCCCCCCCC(O)=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 ONAIRGOTKJCYEY-XXDXYRHBSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108050009160 DNA polymerase 1 Proteins 0.000 description 1
- 241000235035 Debaryomyces Species 0.000 description 1
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000589566 Elizabethkingia meningoseptica Species 0.000 description 1
- 241000178951 Endomyces Species 0.000 description 1
- 241001495410 Enterococcus sp. Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241001465321 Eremothecium Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241001149669 Hanseniaspora Species 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000271915 Hydrophis Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 241001149698 Lipomyces Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 101710132682 Lysozyme 1 Proteins 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 244000235756 Microcos paniculata Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- AOMUHOFOVNGZAN-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)dodecanamide Chemical group CCCCCCCCCCCC(=O)N(CCO)CCO AOMUHOFOVNGZAN-UHFFFAOYSA-N 0.000 description 1
- SUZRRICLUFMAQD-UHFFFAOYSA-N N-Methyltaurine Chemical compound CNCCS(O)(=O)=O SUZRRICLUFMAQD-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002675 Polyoxyl Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001489223 Saccharomycodes Species 0.000 description 1
- 241000235003 Saccharomycopsis Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 241000311088 Schwanniomyces Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- VBIIFPGSPJYLRR-UHFFFAOYSA-M Stearyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)C VBIIFPGSPJYLRR-UHFFFAOYSA-M 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194024 Streptococcus salivarius Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- GCSPRLPXTPMSTL-IBDNADADSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GCSPRLPXTPMSTL-IBDNADADSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 150000004996 alkyl benzenes Chemical class 0.000 description 1
- 210000001132 alveolar macrophage Anatomy 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002216 antistatic agent Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
- 108010055059 beta-Mannosidase Proteins 0.000 description 1
- 239000007621 bhi medium Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000012709 brilliant black BN Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- UDHMTPILEWBIQI-UHFFFAOYSA-N butyl naphthalene-1-sulfonate;sodium Chemical compound [Na].C1=CC=C2C(S(=O)(=O)OCCCC)=CC=CC2=C1 UDHMTPILEWBIQI-UHFFFAOYSA-N 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- OKBPCTLSPGDQBO-UHFFFAOYSA-L disodium;dichloride Chemical compound [Na+].[Na+].[Cl-].[Cl-] OKBPCTLSPGDQBO-UHFFFAOYSA-L 0.000 description 1
- YVIGPQSYEAOLAD-UHFFFAOYSA-L disodium;dodecyl phosphate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOP([O-])([O-])=O YVIGPQSYEAOLAD-UHFFFAOYSA-L 0.000 description 1
- JWEBAGKDUWFYTO-UHFFFAOYSA-L disodium;hydrogen phosphate;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O JWEBAGKDUWFYTO-UHFFFAOYSA-L 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- SYELZBGXAIXKHU-UHFFFAOYSA-N dodecyldimethylamine N-oxide Chemical compound CCCCCCCCCCCC[N+](C)(C)[O-] SYELZBGXAIXKHU-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002557 fixed macrophage Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- NVVZQXQBYZPMLJ-UHFFFAOYSA-N formaldehyde;naphthalene-1-sulfonic acid Chemical compound O=C.C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 NVVZQXQBYZPMLJ-UHFFFAOYSA-N 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000002080 free macrophage Anatomy 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002070 germicidal effect Effects 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940095098 glycol oleate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- RNYJXPUAFDFIQJ-UHFFFAOYSA-N hydron;octadecan-1-amine;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[NH3+] RNYJXPUAFDFIQJ-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011862 kidney biopsy Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 229940031957 lauric acid diethanolamide Drugs 0.000 description 1
- 229940071085 lauroyl glutamate Drugs 0.000 description 1
- 229940094506 lauryl betaine Drugs 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- LENJKGYKZKGAQS-UHFFFAOYSA-L magnesium;diiodide;hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[I-].[I-] LENJKGYKZKGAQS-UHFFFAOYSA-L 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical group CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000004957 naphthylene group Chemical group 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- WXVUCMFEGJUVTN-UHFFFAOYSA-N phenyl methanesulfonate Chemical compound CS(=O)(=O)OC1=CC=CC=C1 WXVUCMFEGJUVTN-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000004915 pus Anatomy 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 238000000763 radioactive isotope labeling Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229940080236 sodium cetyl sulfate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- BTURAGWYSMTVOW-UHFFFAOYSA-M sodium dodecanoate Chemical compound [Na+].CCCCCCCCCCCC([O-])=O BTURAGWYSMTVOW-UHFFFAOYSA-M 0.000 description 1
- 229940082004 sodium laurate Drugs 0.000 description 1
- OGRPJZFGZFQRHZ-UHFFFAOYSA-M sodium;4-octoxy-4-oxo-3-sulfobutanoate Chemical group [Na+].CCCCCCCCOC(=O)C(S(O)(=O)=O)CC([O-])=O OGRPJZFGZFQRHZ-UHFFFAOYSA-M 0.000 description 1
- DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical group [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000011410 subtraction method Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 1
- 235000012756 tartrazine Nutrition 0.000 description 1
- 229960000943 tartrazine Drugs 0.000 description 1
- 239000004149 tartrazine Substances 0.000 description 1
- MUUHXGOJWVMBDY-UHFFFAOYSA-L tetrazolium blue Chemical compound [Cl-].[Cl-].COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC=CC=2)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 MUUHXGOJWVMBDY-UHFFFAOYSA-L 0.000 description 1
- 150000003613 toluenes Chemical class 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
- 108010082737 zymolyase Proteins 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
Definitions
- One type of DNA probe for detection having a chain length of about 350 to about 600 bases The above DNA probe, and
- the temperature at which this enzyme is reacted is about 26 ° C. to about 59 ° C., and the reaction time at which this enzyme is reacted is about 15 minutes to about 120 minutes.
- the DNA and the DNA probe are combined in the presence of a surfactant, especially an anionic surfactant, preferably sodium dodecyl sulfate (SDS). It is hybridized.
- a surfactant especially an anionic surfactant, preferably sodium dodecyl sulfate (SDS).
- FIG. 2 is a view showing a state when the cells are fixed at various leukocyte cell densities.
- FIG. 3 shows the time course of the activity of lytic enzymes on a) Staphylococcus aureus and Staphylococcus epidermidis, (b) Pseudomonas aeruginosa and Escherichia coli, and (c) Enterococcus faecal is.
- Figure 4 shows the concentration dependence of the lytic activity of (a) 300 units / ml of N-acetylmuramidase, (b) 10,000 units / 111 of lysozyme, and (c) 50 units / ml of lysosphin fin by addition of DMS0.
- FIG. 1 shows the concentration dependence of the lytic activity of (a) 300 units / ml of N-acetylmuramidase, (b) 10,000 units / 111 of lysozyme, and (c) 50 units / ml
- FIG. 7 shows the effect of the enzyme treatment on the phagocytic sample, (a) a phagocytic sample of Staphylococcus aureus before the enzyme treatment, (b) a phagocytic sample of Enterococcus faecal is before the enzyme treatment, and (c) It is a figure which shows the state after the sample (a) was subjected to the enzyme treatment, and (d) the state after the sample (b) was subjected to the enzyme treatment.
- Figure 10 shows the results of Southern blots (upper panel) and electrophoresis (lower panel), which show the chain length of the detection probe obtained by digoxigenin labeling of (a) the SA probe and (b) the PA probe and the signal intensity of the label.
- FIG. 10 shows the results of Southern blots (upper panel) and electrophoresis (lower panel), which show the chain length of the detection probe obtained by digoxigenin labeling of (a) the SA probe and (b) the PA probe and the signal intensity of the label.
- the clinical specimen that can be used in the present embodiment may be any clinical specimen containing phagocytes derived from a living body, such as blood, tissue fluid, lymph fluid, cerebrospinal fluid, pus, mucus, runny nose, sputum And other body fluids.
- phagocytes derived from a living body
- a living body such as blood, tissue fluid, lymph fluid, cerebrospinal fluid, pus, mucus, runny nose, sputum And other body fluids.
- phagocytic cells derived from living organisms in the washing solution after washing the nasal cavity, bronchi, skin, various organs, bone, etc. Since these are contained, they can also be used as the clinical specimens of the present invention.
- the slide glass is again immersed in acetone containing about 1 to about 10% APS for 1 minute, immediately washed lightly with acetone and sterile purified water, and then air-dried, preferably at about 20 ° C to about 60 ° C. Can be prepared by drying at about 42 ° C.
- Lysostaphin is an enzyme that reduces the absorbance at 600 nm when Staphylococcus epidermidis and lysostaphin are reacted at 37 ° C for 5 minutes in PBS. If the enzyme activity of Staphylococcus aureus is 37 ° (:, ⁇ 7.5, and the absorbance at 620 nm is reduced from 0.240 to 0.125 in 10 minutes as 1 unit, use 500 units / mg or more. Is preferred.
- a probe diluent was prepared. Apply a solution containing the DNA probe for detection (probe solution) to the smear site, and apply the solution at about 25 to about 50 ° C. Preferably, it is allowed to stand in a wet box at about 37 ° C. to about 42 ° C. for about 1 to about 3 hours, preferably for about 2 hours.
- a blocking operation may be performed. Specifically, 1 ml of a blocking reagent (prepared to a total volume of 10 ml with 2 heron normal serum, 0.5 ml of PBS stock solution, and sterile purified water) per slide glass in a wet box was dropped onto the smear site. Let stand for ⁇ 60 minutes. Then remove the blocking reagent.
- a blocking reagent prepared to a total volume of 10 ml with 2 heron normal serum, 0.5 ml of PBS stock solution, and sterile purified water
- an edible dye for example, yellow No. 4 (tartrazine) can be used to further clarify the signal-cell contrast.
- the substrate is colored purple and the naphthol black is colored blue, so it is difficult to counterstain due to the similar color.
- this method was applied to the present invention, it was found to be useful when performing counterstaining.
- the use of food dyes is an unprecedented method.
- Anionic surfactants are classified into carboxylic acid type, sulfonic acid type, ester sulfate type and phosphate ester type, and nonionic surfactants are ester type, ether type, ester ether type and alkanol type. It is divided into monoamide type.
- Cationic surfactants are classified into an alkylamine salt type and a quaternary ammonium salt type, and amphoteric surfactants are classified into a carboxybetaine type, a 2-alkylimidazoline derivative type and a dalysine type.
- the carboxylic acid form of the anionic surfactant is subdivided into fatty acid monocarboxylates, N-acyl sarcosine salts and N-acyl glutamates.
- fatty acid monocarboxylate includes sodium laurate And N-lasilyl sarcosine salts, N-lauroyl sarcocin sodium, N-lacilyl glutamate and N-lauroyl glutamate.
- Typical examples thereof are polyethylene glycol fatty acid, polyethylene glycol oleate, and fatty acid polyoxyethylene sorbitan, urethane palmitate.
- the alkanolamide type is only one of the fatty acid alkanolamides.
- a representative example is lauric acid diethanolamide.
- Alkylamine salt forms of surfactants include monoalkylamine salts, dialkylamine salts and trialkylamine salts, a typical example being monostearylamine hydrochloride.
- the various surfactants described above are used in the in situ hybridization step, and the method of use is not particularly limited.
- it may be mixed in a probe solution or a probe diluent, or may be mixed with a probe solution.
- a solution containing a surfactant may be added before, simultaneously with, or after the application of the probe solution to the smear site, or a person skilled in the art can make appropriate changes.
- the enzyme used in the DNA exposing step is at least one enzyme selected from the group consisting of lysosomal fin, lysozyme, N-acetylmethylamidase, zymolase, and a surfactant.
- a kit for detecting and / or identifying an infectious disease-causing bacterium, which comprises an added probe solution and at least one DNA probe for detection, is also included.
- the kit contains a blood separation reagent, an enzyme pretreatment reagent, an enzyme reagent, an acetylation reagent, a probe solution, a blocking reagent, a labeled antibody, a labeled antibody diluent, and a color development pretreatment solution, as shown in the examples below.
- the method of the present invention provides accurate results by a very short and simple operation of about 8 hours to complete the entire operation. Especially because It can be a useful marker in the diagnosis and prognosis of infectious diseases such as sepsis or bacteremia that require prompt treatment.
- Enterococcus faecal is inoculated into 50 ml of the BHI liquid medium and cultured at 37 ° C for 8 hours or more. The culture was centrifuged at 2,0Xg for 10 minutes at 4 ° C to collect the cells, suspended in PBS, and then heat-treated with an autoclave (120 ° C, 10 minutes).
- Example 2 5 ml of heparinized healthy human blood was collected, and leukocytes were collected according to the method described in Example 1. Next, leukocytes are suspended in an appropriate amount of PBS, and the number of cells is counted using a hemocytometer. The cell number is adjusted to about 5 ⁇ 10 4 cells / ⁇ to about 2.5 ⁇ 10 5 cells / ⁇ The 5 1 is APS It was smeared on a ride glass well, air-dried, and fixed according to the method of Carnoy fixation described in Example 2. Using this sample, a test was performed according to the methods described in Examples 3 to 11.
- Example 17 (1) 1 and the phagocytic sample of each bacterium prepared in Example 17 (1) 2 were spread on each well of an APS-coated slide glass in an amount of 5 l, and air-dried. Next, immerse in Carnoy's fixative as described in Example 2 for 20 minutes, immerse in 75% ethanol for 5 minutes, wash Carnoy's fixative, air-dry, and store at 4 ° C until use for testing (See Example 2). Then, pretreatment of the fixed sample was performed according to Example 3.
- Example 17 (2) Performed according to the method described in (3).
- a phagocytic sample prepared by the method described in Example 17 (1) 1 and 2 was used as a specimen.
- the phagocytosis rate of the SA digested sample used was 24%, 1.48 ⁇ 10 5 cells / well.
- the phagocytosis rate of the SE-phagocytosed sample was 28%, 2.07 ⁇ 10 5 cells / Pe.
- the phagocytosis rate of the A-phagocytosed sample was 11%, which was 1.59 ⁇ 10 5 cells / Pe.
- the phagocytosis rate of the EF digested sample was 24%, which was 1.72 ⁇ 10 5 cells / per ell.
- the plate was immersed in a 2% blocking reagent (manufactured by Roche) for 30 minutes, and then a 1 / 5,000 amount of an alkaline phosphatase-labeled anti-digoxigenin antibody was added, followed by immersion for 30 minutes.
- the mixture was shaken for 10 minutes with 100 mmol / 1 tris-hydrochloric acid (pH 7.5) and 150 ol / l sodium salt and washed twice. Then, it was washed by shaking with 100 bandol / l Tris-HCl (pH 9.5) and 150 mmol / l sodium chloride for 10 minutes. Thereafter, the color was developed by immersion in an NBT / BCIP solution. Finally, it was immersed in purified water to stop color development and dried. As a result, ⁇ in Fig. 10
- the detection probe was digoxigenin-labeled from EC-24 (SEQ ID NO: 11), EC-34 (SEQ ID NO: 12) and EC-39 (SEQ ID NO: 13) as described in Example 24. And those prepared to have a length of about 350 to about 600 bases were used alone or in combination of three kinds. From the results obtained, as shown in Fig. 11, (a) EC-24, (b) EC-34 or (c) EC-39 were used rather than ( d) It was evident that the mixed probe "MIX" obtained by mixing these could clearly detect the signal and enhance the sensitivity.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60221126T DE60221126T2 (de) | 2001-05-31 | 2002-05-27 | Verbessertes verfahren zum nachweis und zur identifizierung eines eine infektion verursachenden mikroorganismus |
AU2002256921A AU2002256921B2 (en) | 2001-05-31 | 2002-05-27 | Improved method for detecting and identifying microorganism causative of infection |
CA2447750A CA2447750C (en) | 2001-05-31 | 2002-05-27 | Improved method for detecting and identifying causative microorganisms of infectious diseases |
JP2003502242A JP3934605B2 (ja) | 2001-05-31 | 2002-05-27 | 感染症原因微生物の検出および同定のための改良された方法 |
US10/479,185 US7651837B2 (en) | 2001-05-31 | 2002-05-27 | Method for detecting and identifying microorganism causative of infection |
EP02726495A EP1403381B1 (en) | 2001-05-31 | 2002-05-27 | Improved method for detecting and identifying microorganism causative of infection |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-165929 | 2001-05-31 | ||
JP2001165929 | 2001-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002099133A1 true WO2002099133A1 (fr) | 2002-12-12 |
Family
ID=19008541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/005107 WO2002099133A1 (fr) | 2001-05-31 | 2002-05-27 | Procede ameliore de detection et d'identification de micro-organismes causes d'infections |
Country Status (8)
Country | Link |
---|---|
US (1) | US7651837B2 (ja) |
EP (1) | EP1403381B1 (ja) |
JP (1) | JP3934605B2 (ja) |
AT (1) | ATE366824T1 (ja) |
AU (1) | AU2002256921B2 (ja) |
CA (1) | CA2447750C (ja) |
DE (1) | DE60221126T2 (ja) |
WO (1) | WO2002099133A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8187805B2 (en) | 2004-02-09 | 2012-05-29 | Fuso Pharmaceutical Industries, Ltd. | Method of detecting nucleic acid and utilization thereof |
CN111518869A (zh) * | 2020-01-22 | 2020-08-11 | 微岩医学科技(北京)有限公司 | 一种细胞表面脆弱微生物的核酸富集方法及在高通量测序中的应用 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2447775A1 (en) * | 2001-05-31 | 2002-12-19 | Fuso Pharmaceutical Industries, Ltd. | Process for evaluating phagocytotic function and use thereof |
CA2956645A1 (en) | 2003-07-12 | 2005-03-31 | David A. Goldberg | Sensitive and rapid biodetection |
US20120077206A1 (en) | 2003-07-12 | 2012-03-29 | Accelr8 Technology Corporation | Rapid Microbial Detection and Antimicrobial Susceptibility Testing |
JP5196853B2 (ja) * | 2007-05-14 | 2013-05-15 | キヤノン株式会社 | プローブセット、プローブ担体及び検査方法 |
WO2009114520A2 (en) * | 2008-03-10 | 2009-09-17 | Pharmain Corporation | Compositions for treatment with metallopeptidases, methods of making and using the same |
JP2011087571A (ja) * | 2009-09-28 | 2011-05-06 | Sysmex Corp | 細菌分析装置および細菌分析方法 |
US8409807B2 (en) | 2010-10-22 | 2013-04-02 | T2 Biosystems, Inc. | NMR systems and methods for the rapid detection of analytes |
CA2815085C (en) * | 2010-10-22 | 2022-06-21 | T2 Biosystems, Inc. | Nmr systems and methods for the rapid detection of analytes |
US8563298B2 (en) | 2010-10-22 | 2013-10-22 | T2 Biosystems, Inc. | NMR systems and methods for the rapid detection of analytes |
US10254204B2 (en) | 2011-03-07 | 2019-04-09 | Accelerate Diagnostics, Inc. | Membrane-assisted purification |
US9434937B2 (en) | 2011-03-07 | 2016-09-06 | Accelerate Diagnostics, Inc. | Rapid cell purification systems |
EP2839038B1 (en) | 2012-04-20 | 2019-01-16 | T2 Biosystems, Inc. | Compositions and methods for detection of candida species |
US9677109B2 (en) | 2013-03-15 | 2017-06-13 | Accelerate Diagnostics, Inc. | Rapid determination of microbial growth and antimicrobial susceptibility |
DK178306B1 (en) * | 2013-06-16 | 2015-11-23 | Stender Diagnostics V Henrik Stender | Determination of Intracellular Bacteria |
US10253355B2 (en) | 2015-03-30 | 2019-04-09 | Accelerate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
WO2016161022A2 (en) | 2015-03-30 | 2016-10-06 | Accerlate Diagnostics, Inc. | Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing |
WO2017127731A1 (en) | 2016-01-21 | 2017-07-27 | T2 Biosystems, Inc. | Nmr methods and systems for the rapid detection of bacteria |
CN109200063A (zh) * | 2017-06-29 | 2019-01-15 | 中山大学 | 脆弱拟杆菌在制备用于治疗和预防结核病的药物中的应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010411A1 (en) * | 1988-04-20 | 1989-11-02 | Fuso Yakuhin Kogyo Kabushiki Kaisha | Method for diagnosis of infectious diseases and method of detecting and identifying microorganisms |
WO1994001583A1 (en) * | 1992-07-07 | 1994-01-20 | Fuso Pharmaceutical Industries, Ltd. | Probe for diagnosing infectious disease |
WO1994010341A1 (en) * | 1992-10-23 | 1994-05-11 | Fuso Pharmaceutical Industries, Ltd. | Probe for diagnosing infectious diseases |
WO1994028115A1 (de) * | 1993-06-01 | 1994-12-08 | Ortwin Faff | Verfahren zum direkten und biochemisch funktionellen nachweis von retroviren in biologischen proben |
JPH08205893A (ja) * | 1994-12-08 | 1996-08-13 | Sumitomo Metal Ind Ltd | Hcvプロテアーゼ活性測定法 |
WO1996031522A1 (en) * | 1995-04-03 | 1996-10-10 | New York University | Methods for measuring physical characteristics of nucleic acids by microscopic imaging |
WO1999054502A1 (en) * | 1998-04-20 | 1999-10-28 | Academisch Ziekenhuis Groningen | Method for the rapid determination of bacteria |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA792410B (en) | 1978-05-22 | 1980-08-27 | R Sharp | Production of enzymes |
GB2021594B (en) | 1978-05-22 | 1982-10-20 | Atkinson A | Glycerol dehydrogenase |
NL8401221A (nl) | 1984-04-16 | 1985-11-18 | Innovi Nv | Analytische toepassing van fagocyt-cellijnen. |
US5364790A (en) * | 1993-02-16 | 1994-11-15 | The Perkin-Elmer Corporation | In situ PCR amplification system |
DE69432658T2 (de) * | 1993-03-19 | 2004-04-08 | Gunnar Lindahl | Rib-protein, ein oberflächenprotein welches immunität gegen viele streptococcus-stämme der gruppe b verleiht, reinigungsverfahren für das rib-protein, testsatz und pharmazeutische zusammenstellung (arznei) |
US5582985A (en) * | 1994-08-05 | 1996-12-10 | The Regents Of The University Of California | Detection of mycobacteria |
EP0927269A1 (en) * | 1996-09-16 | 1999-07-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by The Secretary, Department of Health and Human Services | Methods and compositions for the detection of candida spp. |
CA2447775A1 (en) * | 2001-05-31 | 2002-12-19 | Fuso Pharmaceutical Industries, Ltd. | Process for evaluating phagocytotic function and use thereof |
-
2002
- 2002-05-27 DE DE60221126T patent/DE60221126T2/de not_active Expired - Lifetime
- 2002-05-27 JP JP2003502242A patent/JP3934605B2/ja not_active Expired - Lifetime
- 2002-05-27 AT AT02726495T patent/ATE366824T1/de active
- 2002-05-27 US US10/479,185 patent/US7651837B2/en not_active Expired - Fee Related
- 2002-05-27 CA CA2447750A patent/CA2447750C/en not_active Expired - Fee Related
- 2002-05-27 AU AU2002256921A patent/AU2002256921B2/en not_active Ceased
- 2002-05-27 WO PCT/JP2002/005107 patent/WO2002099133A1/ja active IP Right Grant
- 2002-05-27 EP EP02726495A patent/EP1403381B1/en not_active Expired - Lifetime
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989010411A1 (en) * | 1988-04-20 | 1989-11-02 | Fuso Yakuhin Kogyo Kabushiki Kaisha | Method for diagnosis of infectious diseases and method of detecting and identifying microorganisms |
WO1994001583A1 (en) * | 1992-07-07 | 1994-01-20 | Fuso Pharmaceutical Industries, Ltd. | Probe for diagnosing infectious disease |
WO1994010341A1 (en) * | 1992-10-23 | 1994-05-11 | Fuso Pharmaceutical Industries, Ltd. | Probe for diagnosing infectious diseases |
WO1994028115A1 (de) * | 1993-06-01 | 1994-12-08 | Ortwin Faff | Verfahren zum direkten und biochemisch funktionellen nachweis von retroviren in biologischen proben |
JPH08205893A (ja) * | 1994-12-08 | 1996-08-13 | Sumitomo Metal Ind Ltd | Hcvプロテアーゼ活性測定法 |
WO1996031522A1 (en) * | 1995-04-03 | 1996-10-10 | New York University | Methods for measuring physical characteristics of nucleic acids by microscopic imaging |
WO1999054502A1 (en) * | 1998-04-20 | 1999-10-28 | Academisch Ziekenhuis Groningen | Method for the rapid determination of bacteria |
Non-Patent Citations (2)
Title |
---|
G.J. JANSEN ET AL.: "Rapid identification of bacteria in blood cultures by using fluorescently labeled oligonucleotide probes", JOURNAL OF CLINICAL MICROBIOLOGY, vol. 38, no. 2, February 2000 (2000-02-01), pages 814 - 817, XP002956567 * |
MATSUHISA AKIKO ET AL.: "Detection of bacteria in phagocyte-smears from septicemia-suspected blood by in situ hybridization using biotinylated probes", MICROBIOL. IMMUNOL., vol. 38, no. 7, 1994, pages 511 - 517, XP002956568 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8187805B2 (en) | 2004-02-09 | 2012-05-29 | Fuso Pharmaceutical Industries, Ltd. | Method of detecting nucleic acid and utilization thereof |
CN111518869A (zh) * | 2020-01-22 | 2020-08-11 | 微岩医学科技(北京)有限公司 | 一种细胞表面脆弱微生物的核酸富集方法及在高通量测序中的应用 |
CN111518869B (zh) * | 2020-01-22 | 2023-03-28 | 微岩医学科技(北京)有限公司 | 一种细胞表面脆弱微生物的核酸富集方法及在高通量测序中的应用 |
Also Published As
Publication number | Publication date |
---|---|
US20060234219A1 (en) | 2006-10-19 |
US7651837B2 (en) | 2010-01-26 |
ATE366824T1 (de) | 2007-08-15 |
DE60221126D1 (de) | 2007-08-23 |
JP3934605B2 (ja) | 2007-06-20 |
CA2447750A1 (en) | 2002-12-12 |
CA2447750C (en) | 2012-12-18 |
EP1403381A4 (en) | 2005-01-12 |
EP1403381B1 (en) | 2007-07-11 |
DE60221126T2 (de) | 2008-03-13 |
EP1403381A1 (en) | 2004-03-31 |
JPWO2002099133A1 (ja) | 2004-09-16 |
AU2002256921B2 (en) | 2006-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002099133A1 (fr) | Procede ameliore de detection et d'identification de micro-organismes causes d'infections | |
JP2008194057A (ja) | 食細胞機能の評価方法およびその利用 | |
EP0133671B1 (en) | Detection of bacteria by nucleic acid hybridization, labeled probes and test kit therefore | |
EP1924252B1 (en) | Method for improving cell permeability to foreign particles | |
CA2332510C (en) | In situ hybridization method for detecting target nucleic acid | |
JPH0771519B2 (ja) | 微生物の感受性測定法 | |
EP0438115A2 (en) | Process for detection of water-borne microbial pathogens and indicators of human fecal contamination in water samples and kits therefor | |
EP0133288A2 (en) | Bacterial detection by nucleic acid hybridization, labeled probes and test kit therefore | |
JPH10503655A (ja) | ミコバクテリアの検出 | |
US8758990B2 (en) | Methods for detecting and differentiating Mycobacterium genus and Mycobacterium avium complex in a sample or culture | |
CA2719863C (en) | Detection and enumeration of microorganisms | |
JP4104377B2 (ja) | シュードモナス・アエルギノーザ菌の検出用プローブおよびそれを用いた方法 | |
JP2004173628A (ja) | ヘモフィリスインフルエンザ菌の検出用プローブおよびそれを用いた方法 | |
JP2009535052A (ja) | 微生物の検出および計数方法 | |
JP4234986B2 (ja) | エシェリヒアコリ菌の検出用プローブおよびそれを用いた方法 | |
JPH03206899A (ja) | クリプトコックス・ネオホルマンスの検出に用いる核酸プローブおよび方法 | |
RU2567011C2 (ru) | ЗОНД ПЕПТИДНО-НУКЛЕИНОВОЙ КИСЛОТЫ, НАБОР И СПОСОБ ОБНАРУЖЕНИЯ И/ИЛИ КОЛИЧЕСТВЕННОГО ОПРЕДЕЛЕНИЯ Salmonella spp. И ИХ ПРИМЕНЕНИЯ | |
JP2004089046A (ja) | カンジダアルビカンス菌の検出用プローブおよびそれを用いた方法 | |
AU2003226729A1 (en) | Method for the identification of microorganisms by means of in situ hybridization and flow cytometry | |
AU2007203571A1 (en) | Method of Evaluating the Function of Phagocyte and Utilization Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003502242 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2447750 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002256921 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002726495 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002726495 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006234219 Country of ref document: US Ref document number: 10479185 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10479185 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002726495 Country of ref document: EP |